



vTv Therapeutics Presents Data on Two Diabetes Candidates at Keystone Symposia on New Therapeutics for Diabetes and Obesity

04/20/16

Data featured in an oral presentation show TTP273 is the first GLP-1R agonist without significant gastrointestinal side effects

HIGH POINT, N.C.--(BUSINESS WIRE)--Apr. 20, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced that data from studies of its orally available, small molecule product candidates were reported at the Keystone Symposia on *New Therapeutics for Diabetes and Obesity*. In an oral presentation later today, the Company will review clinical and preclinical data of TTP273, the first small molecule, orally active, GLP-1 receptor agonist (GLP-1R), which is currently in Phase 2 studies. The conference is being held in La Jolla, CA from April 17 – 20, 2016.

In the presentation entitled, "Oral Small Molecule GLP-1 Receptor (GLP-1R) Agonists for Type 2 Diabetes (T2DM) with Negligible Nausea and Vomiting," Phase 1b data will be presented showing that TTP273, vTv's lead GLP-1R agonist product candidate, lowers blood glucose levels in diabetic patients without significant gastrointestinal side effects seen with currently available products. TTP273 was also shown to be safe, and based on the data presented, significant decreases in HbA1c and body weight are expected in the ongoing Phase 2 study.

"GLP-1 receptor agonists are well-validated treatments that provide glycemic control and weight loss for Type 2 diabetes patients," commented Dr. Carmen Valcarce, SVP and Chief Scientific Officer of vTv Therapeutics. "But their limitations—including side effects like nausea and vomiting, and the fact that current products are available only as an injection—have reduced their potential to help many more patients. We believe an orally dosed GLP-1R agonist with significantly reduced rates of nausea and vomiting would bring a truly differentiated product to this substantial market. We're looking forward to revealing results of the ongoing Phase 2 clinical trial at the end of 2016."

Also at the conference, a poster was presented related to TTP399, the Company's Glucokinase Activator (GKA), currently in a Phase 2b trial for the treatment of Type 2 diabetes. In a poster titled, "The Importance of Tissue Selectivity and Preservation of the Physiological Regulation when Targeting Key Metabolic Regulators as Glucokinase," vTv scientists presented evidence of TTP399's liver selectivity. Targeting liver cells is key to the compound's ability to normalize blood glucose without inducing hypoglycemia, dyslipidemia or other toxicities. These data suggest TTP399 may have a superior safety and efficacy profile over previously studied GKA compounds. Data from a controlled Phase 2b trial of TTP399 in Type 2 diabetes patients is expected in the summer of 2016.

A copy of the posters will be made available in the [News & Events](#) section of the Company's website following the presentations.

About Type 2 Diabetes

Type 2 diabetes is the body's inability to properly use insulin to control sugar in the bloodstream. It is the most common type of diabetes (representing 90 to 95% of diabetes patients), imposing a growing burden on healthcare systems globally. The goal of maintaining A1c levels below 7.0% is elusive for patients with this life-long disease. In addition to unregulated glucose, diabetics commonly have a variety of co-morbidities, including heart disease, stroke, high blood pressure, blindness, kidney disease, amputations, dental disease, and central and peripheral nervous system impairment.

About vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160420005217/en/>

Source: vTv Therapeutics Inc.

Investors

The Trout Group
Michael Gibraltar, 646-378-2938
mgibraltar@troutgroup.com

or

Media

BMC Communications

Brad Miles, 646-513-3125
bmiles@bmccommunications.com